An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Trial ID or NCT#

NCT03532542

Status

recruiting iconRECRUITING

Purpose

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Official Title

Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen

Eligibility Criteria

Ages Eligible for Study: 7 Years to 23 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

John W. Day, MD, PhD
John W. Day, MD, PhD
Neuromuscular neurologist, Neurophysiologist
Professor of Neurology (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology

View on ClinicalTrials.gov